Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.

Godela M. Brosnahan

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus

    Collapse Research 
    Collapse research activities and funding
    R21DK107969     (BROSNAHAN, GODELA M)Aug 20, 2016 - Jul 31, 2018
    Feasibility study of metformin therapy in ADPKD
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2018 Feb; 29(2):571-578. PMID: 29118087.
      View in: PubMed
    2. Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int. 2017 Feb; 91(2):493-500. PMID: 27993381.
      View in: PubMed
    3. Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016 Sep; 27(9):2872-84. PMID: 26823553; PMCID: PMC5004648 [Available on 09/01/17].
    4. Moore CG, Spillane S, Simon G, Maxwell B, Rahbari-Oskoui FF, Braun WE, Chapman AB, Schrier RW, Torres VE, Perrone RD, Steinman TI, Brosnahan G, Czarnecki PG, Harris PC, Miskulin DC, Flessner MF, Bae KT, Abebe KZ, Hogan MC. Closeout of the HALT-PKD trials. Contemp Clin Trials. 2015 Sep; 44:48-55. PMID: 26231556.
      View in: PubMed
    5. Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11; 371(24):2267-76. PMID: 25399731; PMCID: PMC4284824.
    6. Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11; 371(24):2255-66. PMID: 25399733; PMCID: PMC4343258.
    7. Klawitter J, Reed-Gitomer BY, McFann K, Pennington A, Klawitter J, Abebe KZ, Klepacki J, Cadnapaphornchai MA, Brosnahan G, Chonchol M, Christians U, Schrier RW. Endothelial dysfunction and oxidative stress in polycystic kidney disease. Am J Physiol Renal Physiol. 2014 Dec 01; 307(11):F1198-206. PMID: 25234311; PMCID: PMC4254971.
    8. Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, Sun H, Perrone RD, Steinman TI, Braun W, Winklhofer FT, Miskulin DC, Rahbari-Oskoui F, Brosnahan G, Masoumi A, Karpov IO, Spillane S, Flessner M, Moore CG, Schrier RW. Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol. 2015 Jan; 13(1):155-64.e6. PMID: 25111236; PMCID: PMC4267913.
    9. Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, Rossetti S. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol. 2014 Nov; 25(11):2399-418. PMID: 24925719; PMCID: PMC4214531.
    10. Brosnahan G. Treatment of hypertension in chronic kidney disease: does one size fit all? A narrative review from a nephrologist's perspective. Curr Hypertens Rev. 2014; 10(3):155-65. PMID: 25567505.
      View in: PubMed
    11. Klawitter J, Klawitter J, McFann K, Pennington AT, Abebe KZ, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Gitomer B, Christians U, Schrier RW. Bioactive lipid mediators in polycystic kidney disease. J Lipid Res. 2014 Jun; 55(6):1139-49. PMID: 24343898; PMCID: PMC4031945.
    12. Fick-Brosnahan GM. Endothelial dysfunction and angiogenesis in autosomal dominant polycystic kidney disease. Curr Hypertens Rev. 2013 Feb; 9(1):32-6. PMID: 23971642.
      View in: PubMed
    13. Brosnahan G, Fraer M. Management of chronic kidney disease: what is the evidence? South Med J. 2010 Mar; 103(3):222-30. PMID: 20134375.
      View in: PubMed
    14. Brosnahan G, Fraer M. Chronic kidney disease: whom to screen and how to treat, part 1: definition, epidemiology, and laboratory testing. South Med J. 2010 Feb; 103(2):140-6. PMID: 20065899.
      View in: PubMed
    15. Banerjee S, Brosnahan G. Polymyalgia rheumatica in a renal transplant patient. J Ark Med Soc. 2008 Nov; 105(5):115-7. PMID: 19006913.
      View in: PubMed
    16. Brosnahan G, Gokden N, Swaminathan S. Acute interstitial nephritis due to deferasirox: a case report. Nephrol Dial Transplant. 2008 Oct; 23(10):3356-8. PMID: 18653899.
      View in: PubMed
    17. Barone GW, Wright CF, Krause MW, Brosnahan GM, Portilla D, Banerjee S, McCowan TC, Culp WC, Yousaf M. Hemodialysis access success: beyond the operating room. Am J Surg. 2007 Nov; 194(5):668-71. PMID: 17936432.
      View in: PubMed
    18. Brosnahan GM. Volume progression in polycystic kidney disease. N Engl J Med. 2006 Aug 17; 355(7):733; author reply 733-4. PMID: 16914712.
      View in: PubMed
    19. Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecder T, Tison L. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol. 2002 Jul; 13(7):1733-9. PMID: 12089368.
      View in: PubMed
    20. Persu A, Devuyst O, Lannoy N, Materne R, Brosnahan G, Gabow PA, Pirson Y, Verellen-Dumoulin C. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2000 Dec; 11(12):2285-96. PMID: 11095651.
      View in: PubMed
    21. Rabetoy G, Hansen M, Brosnahan G, Hartung L. The lady who had muscle cramps and developed thrombotic microangiopathy. Nephrol Dial Transplant. 2000 Sep; 15(9):1464-7. PMID: 10978412.
      View in: PubMed
    22. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000 Mar; 35(3):427-32. PMID: 10692268.
      View in: PubMed
    23. Ecder T, Edelstein CL, Chapman AB, Johnson AM, Tison L, Gill EA, Brosnahan GM, Schrier RW. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 1999 May; 14(5):1113-6. PMID: 10344347.
      View in: PubMed
    Brosnahan's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description
    Physical Neighbors Expand Description

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)